This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street

Key Points Nektar Therapeutics' leading candidate is performing well so far in phase 2 studies. This medicine could disrupt the large and competitive eczema treatment market. Nektar could match Wall Street's estimates in the next year, but the stock remains risky. 10 stocks we like better than Nektar Therapeutics › Nektar Therapeutics (NASDAQ: NKTR) is a small-cap biotech that has garnered plenty of attention this year. The company's shares have soared, increasing by 285% since January. Yet, some ...